Spectrum Pharmaceuticals Highlights Five Abstracts on ROLONTIS™ (eflapegrastim) and Poziotinib at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, December 6-10, 2016
For more information about the SABCS meeting and for a complete list of abstracts, please refer to the conference website at http://www.abstracts2view.com/sabcs/.
The following are key ROLONTISTM (eflapegrastim) related abstracts being presented at the SABCS meeting:
Abstract # | Type | Title | First Author |
Date/Time Location: Hall 1 |
|||||||||
OT1-01-11 | Poster |
Randomized phase 3 study of a novel, long-acting G-CSF (eflapegrastim) versus pegfilgrastim in the management of chemotherapy-induced neutropenia in early-stage breast cancer patients receiving docetaxel and cyclophosphamide (TC) (ADVANCE study)
|
Schwartzberg |
|
|||||||||
P5-11-09 | Poster |
Sustained efficacy of eflapegrastim in breast cancer patients in a phase 2, open-label, dose-ranging study
|
Vacirca |
|
|||||||||
P5-11-07 | Poster |
Pharmacokinetics of eflapegrastim in a phase 2 open-label dose-ranging study in breast cancer patients receiving TC regimen
|
Vacirca |
|
|||||||||
P5-11-08 | Poster |
Immunogenicity of eflapegrastim in a Phase 2 Open-Label Dose-Ranging Study of eflapegrastim in Breast Cancer Patients Receiving TC Regimen
|
Vacirca |
|
The following key poziotinib related abstract will be presented at the SABCS meeting:
Abstract # | Type | Title | First Author |
Date/Time Location: Hall 1 |
||||||||
OT1-02-10 | Poster |
A phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer (MBC) who have received prior HER2 regimens for MBC
|
Lathrop |
|
About
Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in Hematology and Oncology. Spectrum currently markets six hematology/oncology drugs, and has an advanced stage pipeline that has the potential to transform the Company. Spectrum's strong track record for in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in advanced-stage Phase 2 and Phase 3 studies. More information on Spectrum is available at www.sppirx.com.
Forward-looking statement — This press release may contain
forward-looking statements regarding future events and the future
performance of
© 2016
View source version on businesswire.com: http://www.businesswire.com/news/home/20161205005150/en/
Vice President, Strategic
Planning & Investor Relations
702-835-6300
InvestorRelations@sppirx.com
Source:
News Provided by Acquire Media